Stanford's StartX Fund has contributed to a series B round for UBiome, which will use the money to drive recruitment and conduct tests at its clinical lab.
US-based biotechnology company UBiome has raised $22m in a series B round that featured Stanford University’s StartX Fund, TechCrunch reported earlier today.
The round was led by 8VC, while Slow Ventures and assorted angel investors also supplied cash.
UBiome emerged out of accelerator Y Combinator in 2012. The company has developed a test to sequence the DNA of microorganisms found in fecal matter, and has so far collected nearly 100,000 in gut samples in its database.
Identifying these bacteria is expected to have applications for the detection and treatment of a variety of diseases, including cancer, diabetes, multiple sclerosis, liver disease, obesity and irritable bowel syndrome.
The money will go towards the launch of the company’s testing at its recently accredited clinical lab and will also help drive recruitment.
In 2014, Andreessen Horowitz led a $4.5m series A round that also featured a range of private investors. UBiome also raised approximately $360,000 in a crowdfunding campaign in 2013 to produce its home screening kit.
